Postremission cytopenia management in patients with acute
myeloid leukemia treated with venetoclax and azacitidine in
VIALE-A

J 2022

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

PRATZ, Keith W, Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO et. al.

Basic information

Original name

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Authors

PRATZ, Keith W (guarantor), Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO, Marina KONOPLEVA, Don STEVENS, Hagop KANTARJIAN, Fabiola TRAINA, Adriano VENDITTI, Jiří MAYER (203 Czech Republic, belonging to the institution), Melissa MONTEZ, Huan JIN, Yinghui DUAN, Deanna BRACKMAN, Jiuhong ZHA, Jalaja POTLURI, Michael WERNER and Brian A JONAS

Edition

American Journal of Hematology, Hoboken, John Wiley & Sons, 2022, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 12.800

RIV identification code

RIV/00216224:14110/22:00128097

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ajh.26692

UT WoS

000854058000001

Keywords in English

postremission cytopenia management; acute myeloid leukemia; venetoclax; azacitidine

Abstract

V originále

The phase 3 VIALE-A study (NCT02993523) of venetoclax (Ven) + azacitidine (Aza) demonstrated significantly improved median overall survival (OS; 14.7 months) compared with placebo (Pbo) + Aza in patients with newly diagnosed acute myeloid leukemia (AML) who were aged ≥75 years or ineligible for intensive chemotherapy. The study protocol recommended dosing schedule modification following remission to mitigate hematologic adverse events (AEs; Figure 1A); these occurred in 83% of patients in the Ven + Aza arm. This post hoc analysis of VIALE-A evaluated the frequency and management of postremission cytopenia events, Ven exposure-response relationship with postremission cytopenias, and outcomes when dosing schedule modifications were required for grade 4 cytopenias.

Citovat

PRATZ, Keith W, Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO, Marina KONOPLEVA, Don STEVENS, Hagop KANTARJIAN, Fabiola TRAINA, Adriano VENDITTI, Jiří MAYER, Melissa MONTEZ, Huan JIN, Yinghui DUAN, Deanna BRACKMAN, Jiuhong ZHA, Jalaja POTLURI, Michael WERNER and Brian A JONAS. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. American Journal of Hematology. Hoboken: John Wiley & Sons, 2022, vol. 97, No 11, p. "E416"-"E419", 4 pp. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.26692.

@article{2247608,
   author = {Pratz, Keith W and DiNardo, Courtney D and Selleslag, Dominik and Li, Junmin and Yamamoto, Kazuhito and Konopleva, Marina and Stevens, Don and Kantarjian, Hagop and Traina, Fabiola and Venditti, Adriano and Mayer, Jiří and Montez, Melissa and Jin, Huan and Duan, Yinghui and Brackman, Deanna and Zha, Jiuhong and Potluri, Jalaja and Werner, Michael and Jonas, Brian A},
   article_location = {Hoboken},
   article_number = {11},
   doi = {http://dx.doi.org/10.1002/ajh.26692},
   keywords = {postremission cytopenia management; acute myeloid leukemia; venetoclax; azacitidine},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A},
   url = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26692},
   volume = {97},
   year = {2022}
}

TY  - JOUR
ID  - 2247608
AU  - Pratz, Keith W - DiNardo, Courtney D - Selleslag, Dominik - Li, Junmin - Yamamoto, Kazuhito - Konopleva, Marina - Stevens, Don - Kantarjian, Hagop - Traina, Fabiola - Venditti, Adriano - Mayer, Jiří - Montez, Melissa - Jin, Huan - Duan, Yinghui - Brackman, Deanna - Zha, Jiuhong - Potluri, Jalaja - Werner, Michael - Jonas, Brian A
PY  - 2022
TI  - Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A
JF  - American Journal of Hematology
VL  - 97
IS  - 11
SP  - "E416"-"E419"
EP  - "E416"-"E419"
PB  - John Wiley & Sons
SN  - 03618609
KW  - postremission cytopenia management
KW  - acute myeloid leukemia
KW  - venetoclax
KW  - azacitidine
UR  - https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26692
N2  - The phase 3 VIALE-A study (NCT02993523) of venetoclax (Ven) + azacitidine (Aza) demonstrated significantly improved median overall survival (OS; 14.7 months) compared with placebo (Pbo) + Aza in patients with newly diagnosed acute myeloid leukemia (AML) who were aged ≥75 years or ineligible for intensive chemotherapy. The study protocol recommended dosing schedule modification following remission to mitigate hematologic adverse events (AEs; Figure 1A); these occurred in 83% of patients in the Ven + Aza arm. This post hoc analysis of VIALE-A evaluated the frequency and management of postremission cytopenia events, Ven exposure-response relationship with postremission cytopenias, and outcomes when dosing schedule modifications were required for grade 4 cytopenias.
ER  -

PRATZ, Keith W, Courtney D DINARDO, Dominik SELLESLAG, Junmin LI, Kazuhito YAMAMOTO, Marina KONOPLEVA, Don STEVENS, Hagop KANTARJIAN, Fabiola TRAINA, Adriano VENDITTI, Jiří MAYER, Melissa MONTEZ, Huan JIN, Yinghui DUAN, Deanna BRACKMAN, Jiuhong ZHA, Jalaja POTLURI, Michael WERNER and Brian A JONAS. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2022, vol.~97, No~11, p.~''E416''-''E419'', 4 pp. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.26692.

Detailed Information on Publication Record